Document:

exv10w105

 

Exhibit 10.105

SEVERANCE AGREEMENT AND GENERAL RELEASE

     1. Purpose of Agreement. The purpose of this Severance Agreement and General Release
(“Agreement”) is to confirm the terms of separation of Roger Hawley (“Mr. Hawley”) from his
employment with InterMune, Inc. (“InterMune”) (collectively the “Parties”).

     2. Separation Date. Mr. Hawley’s separation date is January 6, 2006. Mr. Hawley
acknowledges that he has been paid all wages, except for his 2005 annual cash bonus, and accrued,
unused vacation through the Separation Date. The 2005 annual cash bonus will be paid upon the
approval of bonuses for the entire Executive Committee by the Compensation Committee of the
InterMune Board of Directors and at the same time that bonuses are paid to the remaining members of
the Executive Committee. The corporate component of the bonus will be in the amount approved by
the Compensation Committee and the individual component shall be determined in the discretion of
the Chief Executive Officer of InterMune, but in no event shall the total bonus be less than
$100,000.00, less required withholding.

     3. Preserving Confidentiality Of InterMune Proprietary Information. Mr. Hawley
acknowledges and agrees that he has a continuing obligation after the Separation Date to preserve
the confidentiality of all InterMune proprietary information and he shall continue to comply with
the terms and conditions of the Employee Proprietary Information and Inventions Agreement between
him and InterMune. Mr. Hawley further acknowledges that he has returned to InterMune all InterMune
property and confidential and proprietary information in his possession.

     4. Consideration. In exchange for a general release of claims as provided in this
Agreement, InterMune agrees to provide Mr. Hawley with the following consideration.

          a. InterMune will provide Mr. Hawley a severance payment equivalent to 18 months’ base salary,
totaling $518,250.00, less required withholding. This payment shall be made in a lump sum on the
Effective Date (as defined in Paragraph 13 of this Agreement).

          b. InterMune will pay the cost of Mr. Hawley’s COBRA premiums for 18 months after the
Separation Date or until he obtains comparable health insurance coverage through a new employer,
whichever is shorter.

          c. InterMune shall permit the acceleration of all stock options awarded to Mr. Hawley as of
the date of this Agreement that otherwise would have vested within the eighteen (18) months
immediately following the Separation Date. Mr. Hawley shall have until December 31, 2006 to
exercise all vested options.

          d. InterMune will provide Mr. Hawley an incentive payment of $400,000.00, less required
withholding, in recognition of the Tango transaction. This payment shall be made on January 6,
2006.

 

 

     Mr. Hawley agrees that the payments and benefits set forth above are not otherwise due to him
and constitute consideration for the releases provided in this Agreement. The consideration paid
under this Paragraph is subject to the terms and conditions of the InterMune Severance Plan, except
as otherwise provided in this Agreement.

     5. General Release of All Claims. In exchange for the consideration provided in
Paragraph 4, Mr. Hawley and his representatives, heirs and assigns completely release and forever
discharge InterMune, its predecessors and successors, its parent, subsidiary and affiliated
companies, and their respective officers, agents, directors, and employees, attorneys and insurers
from all claims, rights, demands, actions, obligations, and causes of action of any and every kind,
nature and character, known or unknown, which he may now have, or has ever had, against them,
arising from or in any way connected with the employment relationship between the Parties, and the
termination of his employment, including but not limited to all wrongful discharge claims, all
claims related to any contracts of employment, express or implied; all claims arising from the
covenant of good faith and fair dealing, express or implied; all tort claims of any nature; all
claims arising under any federal, state, or municipal statute or ordinance; all claims under the
California Fair Employment and Housing Act, Title VII of the Civil Rights Act, the Age
Discrimination In Employment Act, the Americans with Disabilities Act, Family and Medical Leave
Act, the California Family Rights Act, the Employee Retirement Income Security Act, the Fair Labor
Standards Act, the California Labor Code, the federal and California Worker Adjustment and
Retraining Notification Act, and any other laws and regulations relating to employment
discrimination; and any and all claims for compensation, bonuses, severance pay, attorneys’ fees
and costs. This general release of claims applies to all claims arising as of the Effective Date
of this Agreement, with the following exceptions. This general release includes claims of
discrimination or retaliation on the basis of workers’ compensation status, but does not include
workers’ compensation claims. This general release does not include claims for unemployment
benefits or for benefits under COBRA.

     6. Waiver of Unknown Claims. Mr. Hawley expressly waives the provisions of California
Civil Code Section 1542 which provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES
NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING
THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS
SETTLEMENT WITH THE DEBTOR.

Mr. Hawley understands that Section 1542 gives him the right not to release existing claims of
which he is not now aware, unless he voluntarily chooses to waive this right. Having been so
apprised, he voluntarily elects to waive the rights described in Section 1542, and elects to assume
all risks for claims that now exist in his favor, known or unknown.

     7. Compliance With Older Workers Benefit Protection Act. Mr. Hawley acknowledges that
InterMune hereby advises him (1) to consult with an attorney prior to signing this Agreement; (2)
that he has forty-five (45) days in which to consider whether to sign the Agreement; (3) that if he
signs the Agreement he has seven (7) days thereafter to revoke it; and

2

 

     (4) that the Agreement will not become effective, and no payments will be made, until after
this seven-day revocation period elapses. Mr. Hawley further acknowledges that he has received
Older Workers Benefit Protection Act disclosures.

     8. Cal-WARN Notice. Mr. Hawley acknowledges that he received notice of a mass layoff
pursuant to the California Worker Adjustment and Retraining Notification Act on November 28, 2005.
He further acknowledges that he has received pay in lieu of notice for the period between the
Separation Date and the end of the WARN period.

     9. Dispute Resolution. InterMune and Mr. Hawley agree that any and all disputes
arising out of this Agreement and any of the matters herein released shall be subject to binding
arbitration in San Francisco, California before the American Arbitration Association under the
applicable rules. The Parties agree and hereby waive their rights to a jury trial as to matters
arising out of this Agreement and any matters herein released to the extent permitted by law. The
Parties agree that the prevailing party in any arbitration shall be entitled to injunctive relief
in any court of competent jurisdiction to enforce the arbitration award and is further entitled, to
the extent permitted by law, to recover all costs and attorneys’ fees arising from and related to
the arbitration.

     10. Severability. The provisions of this Agreement are contractual and severable. If
any part of this Agreement is at any time held invalid, that part will remain in effect to the
extent allowed by law and all other provisions shall remain in full force and effect.

     11. Governing Law. This Agreement is governed by and construed in accordance with the
laws of the State of California.

     12. Entire Agreement. This Agreement constitutes a single, integrated written
contract expressing the entire agreement between Mr. Hawley and InterMune concerning the subject
matter of this Agreement. There is no other agreement, written or oral, express or implied,
between Mr. Hawley and InterMune with respect to the subject matter of this Agreement. This General
Release may not be modified except in a writing signed by Mr. Hawley and the Chief Executive
Officer of InterMune.

     13. Effective Date. This Agreement shall become effective on the eighth day following
the date on which it is signed by Mr. Hawley, unless he revokes his approval of the Agreement
within seven (7) days after signing it.

	 	 	 	 	 	 	 
	 

	 	 	 	                    ROGER HAWLEY	 	 
	 
	 	 	 	 	 	 
	Dated: January 6, 2006

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	                    INTERMUNE, INC.	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	Dated: January 5, 2006

	 	 	 	 

By: Daniel Welch, Chief Executive Officer
	 	 

3exv10w106

 

Exhibit 10.106

certain material (indicated by an asterisk) has been omitted from this document pursuant to a
request for confidential treatment. the omitted material has been filed separately with the
securities and exchange commission.

AMENDMENT No. 6 to the License Agreement for Interferon Gamma

THIS AMENDMENT NUMBER SIX TO THE LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered
into effective February 27, 2006 (the “Amendment Effective Date”), by and between Genentech, Inc.
(“Genentech”) and InterMune, Inc. (“InterMune”). Genentech and InterMune may each be referred to
herein as a “Party” and jointly as the “Parties.”

RECITALS

     WHEREAS, Genentech and InterMune are each parties to that certain License Agreement for
Interferon Gamma executed on May 5, 1998, as amended to date (the “Agreement”); and

     WHEREAS, Genentech and InterMune desire to further amend the Agreement as specified herein
below.

     NOW, THEREFORE, in consideration of the mutual covenants and conditions hereinafter set forth,
and intending to be legally bound, Genentech and InterMune hereby agree as follows:

1. Except as modified and/or amended herein, all of the terms, covenants and conditions contained
in the Agreement shall remain unchanged and in full force and effect. The term “Agreement”, as
used in the Agreement, and all other instruments and agreements executed thereunder, shall for all
purposes refer to the Agreement as amended by this Amendment. This Amendment may be executed in
counterpart, each of which shall be deemed to be an original, and such counterparts together shall
constitute one instrument. In the event of a conflict among the terms and conditions of this
Amendment, and the Agreement, the following order of precedence shall prevail:

     a. this Amendment; and

     b. the Agreement.

2. Changes to the Agreement. The following changes are hereby made to the Agreement:

          (a) Section 3.2. Section 3.2 is hereby deleted in its entirety and replaced with the
following new Section 3.2:

     “3.2 Diligence. InterMune shall use its Best Efforts to develop and commercialize
Licensed Products in the Field of Use and in the Gene Therapy Field of Use, in accordance
with the development plan roadmap set forth on Exhibit E hereto (the “Development
Plan Roadmap”).”

 

 

          (b) Section 3.3. Section 3.3 is hereby deleted in its entirety and replaced with the
following new Section 3.3:

     “3.3 Review of Clinical Development Plan and Marketing Programs. On or about each
August 1 during the term of this Agreement, InterMune shall supply Genentech with a report
on InterMune’s development and marketing programs for Licensed Products in the Field of Use
and the Gene Therapy Field of Use in the Territory. The report shall include the
following: (i) a description of InterMune’s progress in such programs during the twelve
(12) months prior to the date of each such report, and (ii) a description of InterMune’s
planned development and marketing programs for the twelve (12) months after the date of
each such report. Genentech shall have the right to comment on the development and
marketing programs, and at Genentech’s discretion, the Parties shall meet to discuss and
agree upon changes to such development and marketing programs.”

          (c) Section 3.8. Section 3.8 is hereby deleted in its entirety and replaced with the
following new Section 3.8:

     “3.8 Clinical Development Reports. In connection with InterMune’s reporting
obligations set forth in Section 3.3 hereof with respect to the development of Licensed
Products and clinical studies conducted by InterMune hereunder, InterMune shall provide to
Genentech any information/report set forth in Exhibit F hereto as may be requested by
Genentech in writing. InterMune shall submit such information/report to Genentech as
promptly as reasonably practicable after such reports are completed or such applicable
information is available.”

          (d) Exhibit E. Exhibit E is hereby deleted in its entirety and replaced with the new
Exhibit E attached hereto. 

In Witness Whereof, the Parties have caused this Amendment to be executed by the
respective duly authorized officers as of the date first written above.

	 	 	 	 	 	 	 	 	 
	GENENTECH, INC.	 	 	 	INTERMUNE, INC.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Joseph S. McCracken
	 	 
	 	By:
	 	/s/ Tom Kassberg
	 

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Printed Name: Joseph S. McCracken	 	 	 	Printed Name: Tom Kassberg
	 
	 	 	 	 	 	 	 	 
	Title: VP Business Development	 	 	 	Title: Sr. VP Corporate Development

 

 

Exhibit E

[***]

 

*** Certain information on this page has been omitted and filed separately with the Commission.
Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00099-of-00352.parquet"}]]